Navigation Links
GSK Notice of First Quarter 2009 Financial Results Announcement and Teleconference
Date:4/21/2009

PHILADELPHIA, April 21 /PRNewswire-FirstCall/ -- On Wednesday, April 22, 2009 GlaxoSmithKline plc (NYSE: GSK) will announce its first quarter financial results for the three months ended March 31, 2009. It is anticipated that the announcement will be released to the London Stock Exchange at approximately 7:00 AM EDT.

At 8:30 AM EDT Andrew Witty, Chief Executive Officer, and Julian Heslop, Chief Financial Officer will hold a briefing meeting for analysts and investors. A webcast will begin at the same time as the teleconference and can be accessed directly at www.gsk.com.

To listen in to the live presentation and Q&A session by phone please dial:

          U.S. toll free phone:    1 866 804 8688
          U.S. toll:               1 718 354 1175

          Passcode:                GSK Q1 Results

An archived version of this webcast will be available from the GSK website at approximately 2:00 PM EDT on the same day.


'/>"/>
SOURCE GlaxoSmithKline plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Vermillion, Inc. Announces Receipt of Notice of Noncompliance From Nasdaq
2. Mediware Information Systems, Inc. Receives Notice from the Nasdaq Stock Market
3. Summary Notice of Class Action in Re McKesson HBOC, Inc. Securities Litigation
4. Innocoll Receives Intends to Grant Notices from the European Patent Office for Two European Patent Applications Related to Novel Wound Healing, Biosurgery and Drug Delivery Applications of its CollaRx(R) Technology
5. ULURU Inc. Announces Issuance of Notice of Allowance for Nanoparticle Aggregate Patent
6. Medifast Receives Notice Regarding NYSE Listing
7. Melanomas may appear noticeably different than other moles
8. Putting the Medical Profession on Notice!: Widow Tells Tragic Story of How Her Husband Died Due to Misdiagnosis and Mistreatment
9. Summary Notice of Proposed Settlement and Settlement Hearing in Re Martek Biosciences Corp., Securities Litigation
10. GenOdyssee Receives Notice of Allowance from U.S. Patent Office for Improved Interferon-Alpha Aimed at Hepatitis C
11. Politics has taken notice of science
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/26/2017)... MO (PRWEB) , ... September 26, 2017 , ... ... agreement for patient scales with Premier Inc. Effective October 1, 2017, the new ... and terms pre-negotiated by Premier for patient scales. , “DETECTO is pleased to ...
(Date:9/26/2017)... ... ... the Millennium”: a gripping take on how the author used personal experience to strengthen ... and do not affect daily choices. It shows how to act like the heirs ... are chosen. “How to Live in the Millennium” is the creation of published author, ...
(Date:9/26/2017)... ... ... “The Ballad of Cowboy Justin”: a charming tale of a brave cowboy who ... creation of published author, Leah Westbrook, a wife and mother who loves to spend ... a delightful tale about a young brave cowboy, Cowboy Justin, who saves the town ...
(Date:9/26/2017)... ... September 26, 2017 , ... “Childhood Memories of a Virginia Wanderer”: ... and help them relive their own youth. “Childhood Memories of a Virginia Wanderer” is ... US Navy for nine years. He received his BS from Idaho State University ...
(Date:9/26/2017)... ... September 26, 2017 , ... “The Tour Guide”: is the life story of the ... creation of published author, David Alexander Stark, is an adventure tour guide and the subject ... around to the back to confront fifteen shocked faces. I played it off as a ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
Breaking Medicine Technology: